Fmr LLC Cardiff Oncology, Inc. Transaction History

Fmr LLC

$1.68 Trillion
Q2 2025

A detailed history of Fmr LLC transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Fmr LLC holds 34,885 shares of CRDF stock, worth $78,491. This represents 0.0% of its overall portfolio holdings.

Number of Shares

34,885

Previous 36,157 3.52%

Holding current value

$78,491

Previous $113,000 3.54%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$2.38 - $4.3 $3,027 - $5,469	-1,272 Reduced 3.52%	34,885 $109,000
Q1 2025 May 12, 2025	BUY	$3.14 - $4.75 $104,408 - $157,942	33,251 Added 1144.22%	36,157 $113,000
Q4 2024 Feb 13, 2025	BUY	$2.31 - $5.35 $3,190 - $7,388	1,381 Added 90.56%	2,906 $12,000
Q3 2024 Nov 13, 2024	BUY	$2.05 - $2.77 $2,511 - $3,393	1,225 Added 408.33%	1,525 $4,000
Q2 2024 Aug 13, 2024	BUY	$2.22 - $5.89 $666 - $1,767	300 New	300 $0
Q3 2023 Nov 13, 2023	SELL	$1.38 - $2.18 $1,333 - $2,105	-966 Reduced 38.03%	1,574 $2,000
Q2 2023 Aug 11, 2023	SELL	$1.37 - $1.95 $6,582 - $9,369	-4,805 Reduced 65.42%	2,540 $3,000
Q1 2023 May 11, 2023	BUY	$1.45 - $2.09 $8,408 - $12,119	5,799 Added 375.1%	7,345 $12,000
Q4 2022 Feb 13, 2023	BUY	$1.22 - $1.66 $128 - $174	105 Added 7.29%	1,546 $2,000
Q3 2022 Nov 10, 2022	SELL	$1.54 - $3.21 $432 - $902	-281 Reduced 16.32%	1,441 $2,000
Q2 2022 Aug 12, 2022	SELL	$1.17 - $2.61 $23,371 - $52,137	-19,976 Reduced 92.06%	1,722 $4,000
Q1 2022 May 13, 2022	BUY	$2.11 - $7.25 $45,782 - $157,310	21,698 New	21,698 $54,000
Q4 2021 Feb 14, 2022	SELL	$5.18 - $7.24 $31 - $43	-6 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$5.01 - $7.58 $30 - $45	6 New	6 $0

Others Institutions Holding CRDF

# of Institutions

126

Shares Held

26.3M

Call Options Held

1.01M

Put Options Held

293K

View Full List

About Cardiff Oncology, Inc.

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $97.5M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

More about CRDF

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account